Amgen Earnings: Here’s Why Shares are Down Now
Amgen Inc. (NASDAQ:AMGN) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 3.87%.
Amgen Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 21.74% to $1.96 in the quarter versus EPS of $1.61 in the year-earlier quarter.
Revenue: Rose 4.69% to $4.24 billion from the year-earlier quarter.
Actual vs. Wall St. Expectations: Amgen Inc. reported adjusted EPS income of $1.96 per share. By that measure, the company beat the mean analyst estimate of $1.84. It missed the average revenue estimate of $4.37 billion.
Quoting Management: “We are on track to deliver our full-year growth objectives,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “In addition, our key pipeline projects are progressing well and we are looking forward to clinical results from ongoing trials.”
Key Stats (on next page)…
Revenue decreased 4.14% from $4.42 billion in the previous quarter. EPS increased 40% from $1.40 in the previous quarter.
Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $1.72 to a profit $1.76. For the current year, the average estimate has moved up from a profit of $7 to a profit of $7.21 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)